News for Amphastar Pharmaceuticals, Inc. (AMPH)

Amphenol Corporation (AMPH) has projected its third-quarter revenue to be in the range of $5.4 billion to $5.5 billion, surpassing market expectations that were

Summary Amphastar Pharmaceuticals Inc (AMPH), a leading biopharmaceutical company, announced on May 22, 2025, that its CFO, Bill Peters, and EVP of Corporate Ad

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 22, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Jacob Liawatidew

Amphastar Pharmaceuticals (AMPH) to participate in Jefferies Global Healthcare Conference on June 5, 2025. The event will feature a fireside chat with C

The Federal Trade Commission (FTC) has intensified its scrutiny over a significant number of device patents associated with several prominent brand-name medicat

On May 12, 2025, JP Morgan analyst Ekaterina Knyazkova issued a downgrade for Amphastar Pharma (AMPH), shifting the rating from "Overweight" to "Neutral". This

In recent developments, JPMorgan has shifted its stance on Amphastar (AMPH), lowering its rating from Overweight to Neutral. This downgrade comes with a reduced

Discover if Amphastar Pharmaceuticals is a buy after Q1 results and a stock dip.

RANCHO CUCAMONGA, CA / ACCESS Newswire / May 9, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP

Amphastar Pharmaceuticals Inc showcases robust product revenues with a slight dip in net income.Investment in R&D and operating expenses reflect a commitment t

On May 1, 2025, Floyd Petersen, Director at Amphastar Pharmaceuticals Inc (AMPH), sold 500 shares of the company. Following this transaction, the insider now ow

With big American pharmaceutical corporations always searching for medications in China, the US pharmaceutical industry is going through a unique trend never seen before.

Recognized for contributions to address shortage of epinephrine injection, 0.1 mg/mL syringes RANCHO CUCAMONGA, CA / ACCESS Newswire / March 28, 2025 / Amphasta

Shares of Amphastar Pharmaceuticals Inc (AMPH) surged 1.36% in mid-day trading on Mar 22. The stock reached an intraday high of $28.44, before settling at $28

Shares of Amphastar Pharmaceuticals Inc (AMPH) surged 0.46% in mid-day trading on Mar 19. The stock reached an intraday high of $27.86, before settling at $27

March 17, 2025 (Maple Hill Syndicate) ”“- The Nasdaq Stock Market led the way up in the great rally of the past two years. Now it's leading the way down.Nasdaq

Amphastar Pharmaceuticals Inc (AMPH) has announced that its CFO, Bill Peters, and EVP of Regulatory Affairs and Clinical Operations, Tony Marrs, will present at

Shares of Amphastar Pharmaceuticals Inc (AMPH) fell 3.24% in mid-day trading on Mar 3. The stock reached an intraday low of $27.29, before recovering slightly

Shares of Amphastar Pharmaceuticals Inc (AMPH) fell 9.30% in mid-day trading on Feb 28. The stock reached an intraday low of $27.82, before recovering slightl